

Endogenous pain modulation profiles among individuals with chronic pain

Relation to opioid use

Martel, Marc O; Petersen, Kristian; Cornelius, Marise; Arendt-Nielsen, Lars; Edwards, Robert

Published in:
Journal of Pain

DOI (link to publication from Publisher):
[10.1016/j.jpain.2018.10.004](https://doi.org/10.1016/j.jpain.2018.10.004)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2019

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Martel, M. O., Petersen, K., Cornelius, M., Arendt-Nielsen, L., & Edwards, R. (2019). Endogenous pain modulation profiles among individuals with chronic pain: Relation to opioid use. *Journal of Pain*, 20(4), 462-471. <https://doi.org/10.1016/j.jpain.2018.10.004>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Manuscript Number: JPAIN-D-18-00543R1

Title: Endogenous pain modulation profiles among individuals with chronic pain: Relation to opioid use

Article Type: Human Study

Keywords: Endogenous pain inhibition; pain facilitation; conditioned pain modulation; temporal summation; opioids; chronic pain

Corresponding Author: Dr. Marc O. Martel, PhD

Corresponding Author's Institution: Harvard Medical School/Brigham & Women's hospital

First Author: Marc O. Martel, PhD

Order of Authors: Marc O. Martel, PhD; Kristian Petersen, PhD; Marise Cornelius, BSc; Lars Arendt-Nielsen, PhD; Robert Edwards, PhD

Abstract: It is generally assumed that individuals exhibiting high pain inhibition also tend to exhibit low pain facilitation, but little research has examined this association in individuals with pain. The aims of this cross-sectional study were 1) to examine the association between measures of conditioned pain modulation (CPM) and temporal summation (TS) in individuals with chronic pain and 2) to examine whether this association was moderated by demographic (age, sex), psychological (depression, catastrophizing), or medication-related (opioid use) variables. individuals (n = 190) with back or neck pain completed questionnaires and underwent a series of quantitative sensory testing (QST) procedures assessing CPM and TS. Results indicated that individuals with higher levels of CPM showed lower levels of TS, $r = -.20$, $p < .01$. Analyses, however, revealed that the magnitude of this association was substantially weaker among opioid users ($r = -.08$, ns) than non-users ($r = -.34$, $p < .01$). None of the demographic or psychological variables included in our study influenced the association between CPM and TS. The magnitude of CPM was lower for opioid users than non-users, suggesting that opioid use might dampen the functioning of endogenous pain-inhibitory systems, and might contribute to a discordance between measures of pain inhibition and pain facilitation.

**Endogenous pain modulation profiles among individuals with chronic pain:
Relation to opioid use**

Marc O. Martel, PhD^{1,2}, Kristian Petersen, PhD⁴, Marise Cornelius, BSc³,
Lars Arendt-Nielsen, PhD⁴, Robert Edwards, PhD³

¹ Faculty of Dentistry, McGill University, Montreal, Canada

² Department of Anesthesia, McGill University, Montreal, Canada

³ Department of Anesthesiology and Pain Medicine, Harvard Medical School, Brigham &
Women's Hospital, Boston, Massachusetts

⁴ SMI®, Department of Health Sciences and Technology, School of Medicine, Aalborg
University, Aalborg, Denmark

Address correspondence to:

Marc O. Martel, PhD. Strathcona Anatomy & Dentistry building, Rm M/71, 3640
University street, Montreal, Qc, Canada, H3A 2B2

Email: marc.o.martel@mcgill.ca

Disclosures

None of the authors have conflicts of interest to declare in relation to the submitted work. *Funding:* This work was supported by grants R21DA041020, and R01AG034982 (RRE, PI) from the National Institutes of Health grants and by a research collaborative grant from the International Association for the Study of Pain (IASP). None of the funding sources were involved in the collection, analysis, or interpretation of data. Funding sources were also not involved in manuscript preparation or in the decision to submit the article for publication.

Abstract

It is generally assumed that individuals exhibiting high pain inhibition also tend to exhibit low pain facilitation, but little research has examined this association in individuals with pain. The aims of this cross-sectional study were 1) to examine the association between measures of conditioned pain modulation (CPM) and temporal summation (TS) in individuals with chronic pain and 2) to examine whether this association was moderated by demographic (age, sex), psychological (depression, catastrophizing), or medication-related (opioid use) variables. individuals ($n = 190$) with back or neck pain completed questionnaires and underwent a series of quantitative sensory testing (QST) procedures assessing CPM and TS. Results indicated that individuals with higher levels of CPM showed lower levels of TS, $r = -.20$, $p < .01$. Analyses, however, revealed that the magnitude of this association was substantially weaker among opioid users ($r = -.08$, ns) than non-users ($r = -.34$, $p < .01$). None of the demographic or psychological variables included in our study influenced the association between CPM and TS. The magnitude of CPM was lower for opioid users than non-users, suggesting that opioid use might dampen the functioning of endogenous pain-inhibitory systems, and might contribute to a discordance between measures of pain inhibition and pain facilitation.

Perspective

Results of the present study indicated that greater endogenous pain-inhibitory capacity is associated with lower levels of pain facilitation. This association, however, was not significant among opioid users, suggesting that opioids might compromise the functioning and interrelationship between endogenous pain modulatory systems.

Keywords

Endogenous pain inhibition; pain facilitation; opioids; chronic pain

1.0. Introduction

It is well known that nociceptive signals can be modulated by central pain inhibitory and facilitatory processes^{1, 8, 82}. These pain-modulatory processes operate at various levels of the central nervous system and are assumed to play a determining role in the manifestations of chronic pain and in shaping inter-individual variability in the trajectory of many persistent pain conditions^{6, 25, 51, 83}. Considerable studies have been conducted using quantitative sensory testing (QST) to assess pain inhibition and pain facilitation^{9, 19, 71}. For instance, conditioned pain modulation (CPM) and temporal summation (TS) paradigms have been used as indices of pain-inhibitory and pain-summation processes^{1, 4, 8}. Evidence of impaired CPM and/or facilitated TS has been observed among individuals with a variety of chronic musculoskeletal, visceral, and neuropathic pain conditions (for reviews, see^{6, 48, 71, 76}).

There has been growing interest in characterizing individuals with chronic pain based on their pain modulation profiles (PMPs)^{4, 8, 56, 84, 86}, as inter-individual variability in pain modulation has been shown to predict clinical outcomes such as development or worsening of pain after surgery^{45, 55, 56}. Studies also found that TS is a predictor of responses to cyclooxygenase-2 (COX-2) inhibitors³ and that CPM is a predictor of responses to topical nonsteroidal anti-inflammatory drugs (NSAID)²⁷ as well as pregabalin treatment^{13, 87}. It has been argued that characterizing individuals with chronic pain based on their pain modulation profiles might provide valuable “mechanistic” information to clinicians in the context of pain assessment and individualized treatment selection^{25, 56, 75, 84, 86}.

One outstanding question in the literature on endogenous pain modulation is the manner in which pain-inhibitory processes (e.g., CPM) and pain-facilitatory processes (e.g., TS) inter-relate. For instance, some have hypothesized a concordance between these measures^{84, 86}, as individuals with low CPM would be expected to exhibit high TS, and vice versa. Psychophysical studies suggest that descending pain-inhibitory systems can modulate pain-facilitatory processes such as temporal summation^{33, 64, 67}. To date, however, it remains unclear whether individual differences in CPM and TS are associated, and very little research has been conducted on the nature of the association between these measures of pain modulation among individuals with chronic pain.

One of the few studies that has grouped together clusters of individuals with pain on the basis of both pain inhibition and pain facilitation reported an interactive effect of these measures, with those who had a combination of poor CPM and elevated TS showing the worst pain after joint replacement surgery⁵⁶. However, that study was not designed to evaluate the basal inter-correlation between CPM and TS, and it is unknown to what extent these factors tend to cluster within individual patients. Moreover, previous studies have shown that endogenous pain inhibition and pain summation may be influenced by a number of demographic variables, such as age and sex^{37, 48, 76}, and by psychological variables such as catastrophizing^{34, 38, 57, 80} and negative affect^{21, 39, 61}, which suggests that any CPM-TS relationships could be influenced by such variables. Furthermore, a number of studies have also shown that medications, such as opioids, may also affect endogenous pain-modulatory processes^{2, 60, 73}. Thus, there is reason to believe that some of these factors could contribute to

enhancing or decreasing the strength of the association between measures of pain inhibition and pain summation among individuals with pain.

The aims of this study were 1) to examine the association between measures of CPM and TS in a large cohort of individuals with chronic pain, 2) to examine the potential moderating role of demographic and psychological factors in the association between CPM and TS, and 3) to investigate the role of opioid use in the association between CPM and TS.

2.0. Methods

2.1. Participants

A sample of 190 individuals with chronic back or neck pain was included in this cross-sectional study. Participants were part of broader study project examining the psychophysical correlates of long-term opioid use. Although some data from the broader parent study were previously published ³⁵, this is our first report specifically examining the association between measures of CPM and TS. Participants in the parent study were recruited via treating physicians at Brigham and Women's Hospital (BWH) and local posting of print advertisements around the BWH Pain Management Center. Participants met the following inclusion criteria: (1) chronic back or neck pain, (2) had been experiencing pain for at least 6 months (3) able to speak, read, and write in English. They were excluded if (4) they had cancer, bone disease, heart disease, or a neurological disease, or (5) cognitive limitations that precluded providing self-report data. Individuals with (6) any active addiction problem (i.e., substance use disorder) were not included in the present study given the current clinical practice guidelines and principles at the BWH Pain Center regarding the management of patients with

substance use disorder (SUD). Patients with active SUD are generally referred to a local addiction treatment facility before undergoing pain treatment at the Pain Center and before being eligible for study participation. For the purposes of the present report, (7) individuals taking non-opioid adjuvant medications in addition to prescription opioids, such as antidepressants, anticonvulsants or sedatives were excluded from the study sample given the potential influence of these medications on endogenous pain modulatory systems ^{5, 7, 36, 79, 89}.

2.2. Procedure & measures

The Human Subjects Committee of BWH approved all study procedures. Interested participants underwent a telephone-based screening before coming in for the study visit. Upon arrival at the laboratory, participants underwent the process of providing informed consent, signed a consent form, and were asked to complete a demographic questionnaire, which included information about age, gender, and ethnicity. Participants also provided information on pain diagnosis and pain duration. They were then asked to report all the medications they were currently taking. Reports of medication were verified by a research assistant after the study session using the electronic medical record system, and published tables ²⁴ were used to convert opioid doses into morphine equivalent daily doses (MEDD). In addition to providing this information, participants were asked to complete self-report questionnaires assessing pain and psychological variables, and then underwent a series of standardized quantitative sensory testing procedures (see below).

2.2.1. Clinical pain severity

The Brief Pain Inventory (BPI ⁷⁴) was used as a measure of chronic pain severity. On the BPI, participants were asked to rate their average level of pain intensity (i.e., over the past 24 hours) on a numeric rating scale (NRS) that ranged from 0 (no pain) to 10 (extreme pain). Participants were also asked to rate the degree to which pain interferes with various domains of functioning on a NRS that ranged from 0 (does not interfere) to 10 (completely interferes). The BPI has been shown to be a reliable and valid measure of pain severity and pain interference among individuals with chronic pain ^{46, 47, 74}.

2.2.2. Pain catastrophizing

The Pain Catastrophizing Scale (PCS ⁶⁸) was used as a measure of catastrophic thinking about pain. The PCS contains 13 items describing different thoughts and feelings that individuals may experience when they are in pain. Participants were asked to reflect on past painful experiences and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on a 5-point scale ranging from 0 (not at all) to 4 (all the time). Numerous studies have supported the reliability and the validity of the PCS as a measure of pain-related catastrophic thinking among individuals with chronic pain ^{26, 54, 70}.

2.2.3. Depressive symptoms

The Beck Depression Inventory (BDI-II ¹⁰) was used as a measure of depressive symptomatology. The BDI-II consists of 21 items describing various symptoms of depression, and participants choose statements that describe how they have been feeling over the past two weeks. Responses are summed to yield an overall index of

depressive symptoms. The BDI has been shown to be a reliable and valid index of depressive symptoms among individuals with chronic pain ^{58, 69, 78}.

2.2.4. Quantitative sensory testing (QST)

During the QST session, participants were seated comfortably in a reclining chair while they underwent a standardized battery of psychophysical pain testing procedures. A trained research assistant sat with participants throughout the QST session. The QST session involved assessment of warmth and cool thresholds, heat pain thresholds (HPTh), cold pain thresholds (CPTh), and heat pain tolerance (HPTo), all tested on the ventral forearm. Pressure pain thresholds (PPT) at the joint of the thumb were also assessed. For purposes of the present study, only the mechanical temporal summation of pain (TS) and conditioned pain modulation (CPM) procedures are described below.

2.2.4.1. Temporal summation

Participants underwent an assessment of mechanical temporal summation using a set of 7 custom-made weighted pinprick stimulators developed by the German research Network on Neuropathic Pain ^{62, 63}. These punctuate mechanical probes have a flat contact area of .2 mm in diameter, and exert forces between 8 and 512 mN. Punctate stimuli were delivered to the skin on the dorsum of the middle finger of the right hand. Participants were first familiarized with the procedure by undergoing a practice trial (on the palm of their hand) during which we determined the lowest force stimulator that produced a painful sensation (128 or 256 mN for most participants). This force was then used to apply a train of 10 stimuli at the rate of 1 per second for the assessment of temporal summation. Participants rated the painfulness of the first, fifth, and tenth stimulus on a 0 to 100 verbal pain intensity scale. An index of temporal

summation was derived by subtracting participants' 1st pinprick pain rating from the last (10th) pinprick pain rating. Higher (positive) scores represented higher levels of temporal summation (i.e., pain facilitation) ^{32, 35}.

2.2.4.2. Conditioned pain modulation

In order to assess CPM, baseline pressure pain thresholds (PPTs) were first assessed using a handheld digital pressure algometer (Somedic, Hörby, Sweden) on the right upper trapezius, approximately 2 cm from the acromioclavicular joint. Given that participants had previously been familiarized with pressure pain threshold (PPT) assessment (assessed at the thumb) earlier during the QST session, CPM testing did not involve any practice trial. During baseline assessment of PPT at the trapezius, mechanical force was applied using a 0.5-cm² probe covered with polypropylene pressure-transducing material. Pressure was increased at a steady rate of 30 kPa/s until the subject indicated that the pressure was “first perceived as painful.” Immediately following the assessment of PPT, participants underwent a cold pressor test (CPT). During the CPT, participants immersed their contralateral (left) hand up to the wrist in a circulating cold water bath maintained at 4°C, a water temperature used as conditioning stimulus in many previous CPM studies ^{12, 38, 64}. Twenty seconds following hand immersion, PPT was reassessed on the right trapezius (i.e., the same site as baseline assessment). Participants were asked to remove their arm from the water 30 seconds after arm immersion. A second CPM trial was conducted two minutes after the end of the first CPM trial. The use of a 2-minute rest period between CPM trials is consistent with procedures that have been used in several previous CPM studies using the cold pressor test as the conditioning stimulus ^{30, 33, 38}. Assessing CPM twice is also

consistent with recommendations on CPM testing.⁸⁵ For each of the CPM trials, a CPM index was derived by calculating the percent ratio of PPT during CPT to PPT prior to CPT. Scores from these two CPM trials were averaged, and higher CPM scores represented greater pain-inhibitory capacity.^{28, 31, 65, 85}

3.0. Data Reduction and Analysis

All data were analyzed using IBM-SPSS v.21 (Chicago, IL, USA). The alpha level for significance was set to $p < .05$ for all analyses, and p-values above .05 are labeled in the Results section as NS (non-significant). Descriptive data for continuous variables were presented as means and standard deviations, and data for categorical variables were presented as percentages. Data for one of the CPM trials were missing for 7% of participants (i.e., 13/190). For these participants, data from the first CPM trial were used for the computation of the final CPM index.

Prior to conducting the primary study analyses, the potential confounding influence of ethnicity, clinical pain intensity, pain interference, and pain duration on CPM and TS was examined. Variables associated either with CPM or TS were retained as covariates in subsequent analyses.

A Pearson correlation was first computed to examine the association between CPM and TS. Pearson correlations were then computed to examine the association between psychological factors (i.e., catastrophizing, depressive symptoms) and endogenous pain modulation measures (i.e., CPM, TS), and independent samples t-tests were used to examine whether CPM and TS scores varied as a function of participant sex (i.e., men/women) and opioid status (i.e., opioid users/non-users).

In order to examine the potential moderating role of age, sex, opioid status, and psychological factors in the association between CPM and TS, five distinct moderation analyses were conducted using the PROCESS macro developed by Hayes et al.⁴³ For each of these moderation analyses, the TS index was used as the dependent variable, and two-way interaction terms between the CPM index and potential moderators (i.e., age, sex, opioid status, catastrophizing, depressive symptoms) were specified after inclusion of appropriate main effects. Any significant two-way interaction effect would suggest that the association between CPM and TS is moderated by participant age, sex, opioid status, catastrophizing, or depressive symptoms. Bias-corrected 95% confidence intervals (CI) were generated based on 5,000 bootstrap resamples, and CIs were presented along with p-values to interpret the significance of interaction/moderation effects. As recommended, moderation effects were considered significant in the case zero was not included within the CIs. Bootstrapping has been widely recommended because it improves power, but it was estimated that our sample size would be sufficient in order to detect medium-to-large effects using bootstrapping with two independent variables (IVs), an alpha set to .05, and a power of .80.⁴³

4.0. Results

4.1. Descriptive statistics

Descriptive statistics are presented in Table 1. In the present sample, 64 % (n = 122) of participants were taking opioids (average daily opioid dose = 101.0 morphine equivalents; SD = 114.8).

Prior to conducting primary analyses, the potential confounding influence of ethnicity, clinical pain intensity, pain interference, and pain duration on primary study

variables (i.e., CPM, TS) was examined. For opioid users, the influence of daily opioid dose on CPM and TS was also examined. None of these variables were significantly associated with either CPM or TS (see Table 2). Opioid users and non-users differed significantly on measures of clinical pain intensity ($t(176) = -7.3, p < .01$) and pain interference ($t(154) = -8.4, p < .01$), but not in pain duration.

4.2. Association between psychological factors and endogenous pain modulation

Table 2 also shows the correlations between psychological factors and endogenous pain modulation measures. Correlational analyses revealed a marginally significant negative association between catastrophizing and CPM ($r = -.14, p = .05$), indicating that higher levels of catastrophizing were associated with lower CPM. A significant positive correlation was found between catastrophizing and TS ($r = .15, p < .05$). Depressive symptoms were not significantly associated with either CPM or TS.

Independent samples t-tests were used to examine whether CPM and TS scores varied as a function of participant sex (i.e., men/women) and opioid status (i.e., opioid users/non-users). Results indicated that there were no significant sex differences either in CPM ($t(188) = 1.8, NS$) or TS ($t(188) = -.62, NS$). Results of t-tests, however, indicated a marginally significant difference in CPM as a function of opioid status, with lower CPM scores for opioid users than non-users, $t(188) = 2.1, p < .05$. Opioid users and non-users did not differ significantly on the TS index, $t(188) = -0.10, NS$ (see Figures 1 and 2).

4.3. Association between CPM and TS

A Pearson correlation was computed to examine the association between CPM and TS. Results revealed a significant negative correlation between CPM and TS

scores ($r = -.20$, $p < .01$), indicating that higher levels of CPM were associated with lower levels of temporal summation.

4.4. Moderators of the association between CPM and TS

As noted previously, five distinct bootstrapped moderation analyses were conducted to examine whether age, sex, opioid status, catastrophizing, or depressive symptoms moderated the association between CPM and TS. Results from these analyses indicated no significant 2-way interactions between CPM and participant age ($B = .001$, $SE = .004$, NS), sex ($B = .053$, $SE = .099$, NS), catastrophizing ($B = -.006$, $SE = .004$, NS), or depressive symptoms ($B = -.001$, $SE = .006$, NS). The two-way interaction effect between CPM and opioid status, however, was significant ($B = .194$, $SE = .091$, $p < .05$; LLCI = .014; ULCI = .375), indicating that the association between CPM and TS was moderated by participants' opioid status. Simple slope analyses were subsequently conducted in order to probe the interaction of CPM and opioid status on TS. As can be seen from Figure 3, the association between CPM and TS varied as a function of participants' opioid status (i.e., opioid users vs non-users). Results revealed a significant association between CPM and TS for non-users ($r = -.34$, $p < .01$), but not for opioid users ($r = -.08$, NS).

5.0. Discussion

Results of this study indicated that greater endogenous pain-inhibitory capacity is associated with lower levels of pain summation. Further, a moderation analysis revealed that the magnitude of this association differed significantly as a function of participants' opioid status, with opioid use appearing to reduce the magnitude of the inverse relationship between CPM and TS. None of the demographic or psychologic variables

included in the present study were found to moderate the association between CPM and TS.

The association that was found between CPM and TS is generally consistent with heuristic models of endogenous pain modulation that implicitly assume a certain degree of concordance between measures of pain inhibition and facilitation^{4, 20, 27, 66, 84, 86}. For instance, individuals exhibiting either high pain inhibition (high CPM), low pain summation (low TS), or both, have been collectively described as having an “antinociceptive” pain modulation phenotype, as opposed to a pro-nociceptive phenotype characterized by high TS and low CPM^{40, 86}. It is also noteworthy that individuals with chronic pain conditions characterized by “dysfunctional” pain modulation tend to show both decrements in CPM and elevations in TS relative to controls^{1, 8, 22, 23, 66}. On the basis of this model, one would expect an inverse association between indices of endogenous pain inhibition and endogenous pain facilitation, which is what we observed in the present study. In addition, two recent studies found that roughly 30 % of individuals with “normal” or “higher-than-average” CPM levels were characterized by low levels of TS^{56, 75}, which is also consistent with our results.

Interestingly, the present study found an association between measures of CPM and TS selectively among individuals who are not using opioids. While a number of factors might account for the altered association between CPM and TS among opioid users, our data suggest that this might be due at least in part to the potentially disruptive effects of exogenous opioids on individuals’ endogenous pain-inhibitory capacity. Consistent with previous work^{29, 59}, we found that the magnitude of CPM was lower for opioid users than non-users, suggesting that opioid use might dampen the functioning

of endogenous pain-inhibitory systems. Interestingly, several recent experimental studies have found that acute opioid administration may enhance endogenous pain inhibition ^{2, 53}, and other reports of short-term administration have suggested minimal effects ⁷³. Collectively, these findings may suggest that the impact of opioid use on indices of pain inhibition shows a biphasic time course, with acute potentiation of CPM followed by long-term decrements of CPM. There is now compelling evidence both from preclinical ^{15, 50} and clinical ^{77, 88} studies that opioid use, over time, may progressively lead to enduring neuroplastic changes at various levels of the central nervous system (CNS), including within neural pathways known to be involved in endogenous pain inhibition. To the extent that endogenous pain-inhibitory systems exert a modulatory influence upon pain summation ^{6, 25, 41, 81}, opioid-induced disruption of pain-inhibitory function might compromise the expected association between pain inhibition and pain facilitation, as observed among opioid users included in the present study. Although speculative, a disruption of pain-inhibitory function as a result of repeated opioid use might contribute to enhanced descending facilitatory activity and, in turn, to opioid-induced hyperalgesia (OIH), a phenomenon observed both experimentally and clinically ^{16, 17, 49, 72}. The observational nature of our study design prevents from concluding that opioid use caused hyperalgesic responses (i.e., opioid-induced hyperalgesia). However, the significantly lower pain-inhibitory (i.e., CPM) function and heightened clinical pain intensity levels observed among opioid users compared to non-users provide partial support for this notion. Previous studies among individuals with chronic pain have also observed disruptions in CPM ^{28, 60, 90} and heightened clinical pain intensity levels ^{17, 18} among long-term opioid users. However, given that these studies were also based on

observational study designs, research will be needed to determine whether a disruption of the association between pain-inhibitory and pain-facilitatory mechanisms may contribute to the development of opioid-induced hyperalgesia among individuals who initiate opioid therapy.

The findings of the present study have not only implications for conceptual models of endogenous pain modulation, but also for the assessment of pain-modulatory profiles in treatment settings. For instance, the modest overlap (i.e., concordance) between measures CPM and TS suggests considerable inter-individual heterogeneity within each of the pain modulation profiles. Consequently, in clinic settings, these two measures should not be used interchangeably to derive inferences about individuals' pain modulation. The predictive consideration of both CPM and TS paradigms is likely to yield a more reliable and comprehensive assessment of pain modulation profiles ⁵⁵. Our findings also suggest that a certain “discordance” between measures of endogenous pain inhibition (i.e., CPM) and pain facilitation (i.e., TS) might be more particularly pronounced among specific subgroups of individuals with chronic pain, such as those using opioid medication. Given that the coupling of high pain inhibition and low pain facilitation is viewed as an optimal pain modulation profile (i.e., an “antinociceptive” PMP) with the potential for buffering against negative pain-related outcomes ^{25, 84, 86}, the putative deleterious impact of opioids on individuals' pain modulation profiles should be considered over the course of treatment selection, either in the context of perioperative or chronic pain management. Future research should also examine whether the association between pain inhibition and pain facilitation is enhanced when individuals

are discontinuing or tapering off opioid medication, as well as the time course of these putative shifts in pain modulation produced by changes in opioid treatments.

A number of limitations must be considered when interpreting the present findings. First, this study report is based on a convenience sample, which limited our explanatory reach in accounting for some of the findings that were reported. Second, due to the cross-sectional nature of the study design, individuals' levels of CPM and TS were assessed only at a single point in time. While these two measures have been found to be relatively stable over time ^{11, 14, 42, 44, 52}, future studies involving repeated assessment of CPM and TS would allow one to derive more reliable inferences about the magnitude of the association between these two forms of endogenous pain modulation. Third, participants in the present study were taking relatively high doses of opioids considering recent changes in opioid prescribing guidelines ²⁴. Daily opioid doses were neither associated with CPM nor TS, but further studies will need to determine whether our findings can be generalized to patients taking lower opioid doses. It will also be important to further evaluate the influence of opioid dose and opioid use duration to the functioning of endogenous pain modulation systems. Fourth, individuals taking non-opioid analgesic medications were not included in the analyses. While this may be seen as a methodological strength, as it permitted us to rule out the influence of non-opioid medication on endogenous pain modulation, this places limits on the generalizability of our findings. Fifth, we did not measure potentially important variables, such as the duration of opioid therapy or the recency of opioid use in relation to QST. Future studies should control for inter-individual differences in these variables as they might influence measures of pain modulation. Finally, CPM was derived only on

the basis of the cold pressor test and pressure pain stimuli. Replication of our findings using other methods or CPM paradigms (i.e., using other conditioning and/or test stimuli) ⁴⁴ is warranted before drawing more firm conclusions regarding the association between CPM and TS.

Conclusion

Findings from the present study provide new insights into the association between endogenous pain-inhibitory and pain summation systems, showing an inverse relationship between CPM and TS among individuals with chronic pain. That is, those exhibiting higher levels of CPM showed lower levels of TS. While the coupling of high pain inhibition and low pain facilitation is viewed as an optimal endogenous pain modulation profile that may buffer against negative pain-related outcomes ^{25, 84}, the present findings suggest that opioid use might disrupt endogenous pain-inhibitory function and, in turn, the association between endogenous pain-inhibitory (i.e., CPM) and pain-facilitatory (TS) systems. Given that an impaired association between pain-inhibitory and pain-facilitatory systems is expected to increase individuals' vulnerability to poor pain-related outcomes ^{25, 56, 84}, further research will be needed to identify the factors that may impair the interrelationship between these endogenous pain modulatory systems. Research will also be needed to determine whether a disruption of the association between pain-inhibitory and pain-facilitatory mechanisms may contribute to long-term sensitization and hyperalgesic responses (i.e., opioid-induced hyperalgesia) among opioid users. Research in this area would provide additional insights into the potentially deleterious impact of opioids on endogenous pain

modulation systems, and would have implications for the management of individuals with pain conditions.

References

1. Arendt-Nielsen L. Central sensitization in humans: assessment and pharmacology. *Handb Exp Pharmacol*. 227:79-102, 2015
2. Arendt-Nielsen L, Andresen T, Malver LP, Oksche A, Mansikka H, Drewes AM. A double-blind, placebo-controlled study on the effect of buprenorphine and fentanyl on descending pain modulation: a human experimental study. *The Clinical journal of pain*. 28:623-627, 2012
3. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. *Pain*. 157:1634-1644, 2016
4. Arendt-Nielsen L, Egsgaard LL, Petersen KK, Eskehave TN, Graven-Nielsen T, Hoeck HC, Simonsen O. A mechanism-based pain sensitivity index to characterize knee osteoarthritis patients with different disease stages and pain levels. *Eur J Pain*. 19:1406-1417, 2015
5. Arendt-Nielsen L, Frokjaer JB, Staahl C, Graven-Nielsen T, Huggins JP, Smart TS, Drewes AM. Effects of gabapentin on experimental somatic pain and temporal summation. *Reg Anesth Pain Med*. 32:382-388, 2007
6. Arendt-Nielsen L, Graven-Nielsen T. Translational musculoskeletal pain research. *Best Pract Res Clin Rheumatol*. 25:209-226, 2011
7. Arendt-Nielsen L, Mansikka H, Staahl C, Rees H, Tan K, Smart TS, Monhemius R, Suzuki R, Drewes AM. A translational study of the effects of ketamine and pregabalin on temporal summation of experimental pain. *Reg Anesth Pain Med*. 36:585-591, 2011
8. Arendt-Nielsen L, Skou ST, Nielsen TA, Petersen KK. Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain. *Curr. Osteoporos. Rep*. 13:225-234, 2015
9. Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, Edwards RR, Freeman R, Gracely R, Haanpaa MH, Hansson P, Hatem SM, Krumova EK, Jensen TS, Maier C, Mick G, Rice AS, Rolke R, Treede RD, Serra J, Toelle T, Tugnoli V, Walk D, Walalce MS, Ware M, Yarnitsky D, Ziegler D. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. *Pain*. 154:1807-1819, 2013
10. Beck A, Steer R, Brown GK: *Manual for the Beck Depression Inventory-II.*, Psychological Corporation: San Antonio, TX, 1996.
11. Biurrun Manresa JA, Neziri AY, Curatolo M, Arendt-Nielsen L, Andersen OK. Test-retest reliability of the nociceptive withdrawal reflex and electrical pain thresholds after single and repeated stimulation in patients with chronic low back pain. *Eur J Appl Physiol*. 111:83-92, 2011
12. Bouhassira D, Moisset X, Jouet P, Duboc H, Coffin B, Sabate JM. Changes in the modulation of spinal pain processing are related to severity in irritable bowel

- syndrome. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*. 25:623-e468, 2013
13. Bouwense SA, Olesen SS, Drewes AM, van Goor H, Wilder-Smith OH. Pregabalin and placebo responders show different effects on central pain processing in chronic pancreatitis patients. *J Pain Res*. 8:375-386, 2015
14. Cathcart S, Winefield AH, Rolan P, Lushington K. Reliability of temporal summation and diffuse noxious inhibitory control. *Pain research & management*. 14:433-438, 2009
15. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. *British journal of pharmacology*. 154:384-396, 2008
16. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. *The Clinical journal of pain*. 24:479-496, 2008
17. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. *The journal of pain : official journal of the American Pain Society*. 7:43-48, 2006
18. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C, Mao J. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. *Reg Anesth Pain Med*. 33:199-206, 2008
19. Cruz-Almeida Y, Fillingim RB. Can quantitative sensory testing move us closer to mechanism-based pain management? *Pain Med*. 15:61-72, 2014
20. Cruz-Almeida Y, King CD, Goodin BR, Sibille KT, Glover TL, Riley JL, Sotolongo A, Herbert MS, Schmidt J, Fessler BJ, Redden DT, Staud R, Bradley LA, Fillingim RB. Psychological profiles and pain characteristics of older adults with knee osteoarthritis. *Arthritis Care Res (Hoboken)*. 65:1786-1794, 2013
21. de Souza JB, Potvin S, Goffaux P, Charest J, Marchand S. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. *The Clinical journal of pain*. 25:123-127, 2009
22. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. *Nat. Rev Rheumatol*. 9:340-350, 2013
23. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. Idiopathic pain disorders--pathways of vulnerability. *Pain*. 123:226-230, 2006
24. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *Jama*. 315:1624-1645, 2016
25. Edwards RR. Individual differences in endogenous pain modulation as a risk factor for chronic pain. *Neurology*. 65:437-443, 2005
26. Edwards RR, Bingham CO, 3rd, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. *Arthritis and rheumatism*. 55:325-332, 2006
27. Edwards RR, Dolman AJ, Martel MO, Finan PH, Lazaridou A, Cornelius M, Wasan AD. Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis. *BMC musculoskeletal disorders*. 17:284, 2016

28. Edwards RR, Dolman AJ, Michna E, Katz JN, Nedeljkovic SS, Janfaza D, Isaac Z, Martel MO, Jamison RN, Wasan AD. Changes in Pain Sensitivity and Pain Modulation During Oral Opioid Treatment: The Impact of Negative Affect. *Pain medicine (Malden, Mass.)*. 2016
29. Edwards RR, Dolman AJ, Michna E, Katz JN, Nedeljkovic SS, Janfaza D, Isaac Z, Martel MO, Jamison RN, Wasan AD. Changes in Pain Sensitivity and Pain Modulation During Oral Opioid Treatment: The Impact of Negative Affect. *Pain Med.* 17:1882-1891, 2016
30. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. *Pain.* 101:155-165, 2003
31. Edwards RR, Grace E, Peterson S, Klick B, Haythornthwaite JA, Smith MT. Sleep continuity and architecture: associations with pain-inhibitory processes in patients with temporomandibular joint disorder. *European journal of pain (London, England)*. 13:1043-1047, 2009
32. Edwards RR, Mensing G, Cahalan C, Greenbaum S, Narang S, Belfer I, Schreiber KL, Campbell C, Wasan AD, Jamison RN. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. *J. Pain Symptom. Manage.* 46:30-42, 2013
33. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in diffuse noxious inhibitory controls (DNIC): association with clinical variables. *Pain.* 106:427-437, 2003
34. Edwards RR, Smith MT, Stonerock G, Haythornthwaite JA. Pain-related catastrophizing in healthy women is associated with greater temporal summation of and reduced habituation to thermal pain. *The Clinical journal of pain.* 22:730-737, 2006
35. Edwards RR, Wasan AD, Michna E, Greenbaum S, Ross E, Jamison RN. Elevated pain sensitivity in chronic pain patients at risk for opioid misuse. *The journal of pain : official journal of the American Pain Society.* 12:953-963, 2011
36. Enggaard TP, Klitgaard NA, Gram LF, Arendt-Nielsen L, Sindrup SH. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. *Clinical pharmacology and therapeutics.* 69:245-251, 2001
37. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL, 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. *The journal of pain : official journal of the American Pain Society.* 10:447-485, 2009
38. Goodin BR, McGuire L, Allshouse M, Stapleton L, Haythornthwaite JA, Burns N, Mayes LA, Edwards RR. Associations between catastrophizing and endogenous pain-inhibitory processes: sex differences. *The journal of pain : official journal of the American Pain Society.* 10:180-190, 2009
39. Granot M, Weissman-Fogel I, Crispel Y, Pud D, Granovsky Y, Sprecher E, Yarnitsky D. Determinants of endogenous analgesia magnitude in a diffuse noxious inhibitory control (DNIC) paradigm: do conditioning stimulus painfulness, gender and personality variables matter? *Pain.* 136:142-149, 2008
40. Granovsky Y, Yarnitsky D. Personalized pain medicine: the clinical value of psychophysical assessment of pain modulation profile. *Rambam. Maimonides. Med. J.* 4:e0024, 2013

41. Graven-Nielsen T, Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. *Nature reviews. Rheumatology*. 6:599-606, 2010
42. Graven-Nielsen T, Vaegter HB, Finocchietti S, Handberg G, Arendt-Nielsen L. Assessment of musculoskeletal pain sensitivity and temporal summation by cuff pressure algometry: a reliability study. *Pain*. 156:2193-2202, 2015
43. Hayes AF: *Introduction to Mediation, Moderation, and Conditional Process Analysis, A Regression-Based Approach Methodology in the Social Sciences*. 2nd edition, Guilford Publications, 2017.
44. Imai Y, Petersen KK, Morch CD, Arendt Nielsen L. Comparing test-retest reliability and magnitude of conditioned pain modulation using different combinations of test and conditioning stimuli. *Somatosens Mot Res*. 33:169-177, 2016
45. Izumi M, Petersen KK, Laursen MB, Arendt-Nielsen L, Graven-Nielsen T. Facilitated temporal summation of pain correlates with clinical pain intensity after hip arthroplasty. *Pain*. 2016
46. Jamison RN, Link CL, Marceau LD. Do pain patients at high risk for substance misuse experience more pain? A longitudinal outcomes study. *Pain medicine (Malden, Mass.)*. 10:1084-1094, 2009
47. Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning? *The journal of pain : official journal of the American Pain Society*. 7:644-653, 2006
48. Lewis GN, Rice DA, McNair PJ. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. *The journal of pain : official journal of the American Pain Society*. 13:936-944, 2012
49. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. *Pain*. 100:213-217, 2002
50. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. *Annals of the New York Academy of Sciences*. 933:175-184, 2001
51. Marchand S. The physiology of pain mechanisms: from the periphery to the brain. *Rheum Dis Clin North Am*. 34:285-309, 2008
52. Martel MO, Wasan AD, Edwards RR. Sex differences in the stability of conditioned pain modulation (CPM) among patients with chronic pain. *Pain medicine (Malden, Mass.)*. 14:1757-1768, 2013
53. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. *Br. J. Anaesth*. 113:148-156, 2014
54. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. *J. Behav. Med*. 23:351-365, 2000
55. Petersen KK, Arendt-Nielsen L, Simonsen O, Wilder-Smith O, Laursen MB. Presurgical assessment of temporal summation of pain predicts the development of chronic postoperative pain 12 months after total knee replacement. *Pain*. 156:55-61, 2015

56. Petersen KK, Graven-Nielsen T, Simonsen O, Laursen MB, Arendt-Nielsen L. Preoperative pain mechanisms assessed by cuff algometry are associated with chronic postoperative pain relief after total knee replacement. *Pain*. 157:1400-1406, 2016
57. Piche M, Bouin M, Arsenault M, Poitras P, Rainville P. Decreased pain inhibition in irritable bowel syndrome depends on altered descending modulation and higher-order brain processes. *Neuroscience*. 195:166-175, 2011
58. Poole H, Bramwell R, Murphy P. Factor Structure of the Beck Depression Inventory-II in patients With chronic pain. *The Clinical journal of pain*. 22:790-798, 2006
59. Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain - new perspective of opioid-induced hyperalgesia. *Pain*. 139:431-438, 2008
60. Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain - new perspective of opioid-induced hyperalgesia. *Pain*. 139:431-438, 2008
61. Robinson ME, Wise EA, Gagnon C, Fillingim RB, Price DD. Influences of gender role and anxiety on sex differences in temporal summation of pain. *The journal of pain : official journal of the American Pain Society*. 5:77-82, 2004
62. Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Botefur IC, Braune S, Flor H, Hoge V, Klug R, Landwehrmeyer GB, Magerl W, Maihofner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. *Pain*. 123:231-243, 2006
63. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede RD. Quantitative sensory testing: a comprehensive protocol for clinical trials. *European journal of pain (London, England)*. 10:77-88, 2006
64. Serrao M, Rossi P, Sandrini G, Parisi L, Amabile GA, Nappi G, Pierelli F. Effects of diffuse noxious inhibitory controls on temporal summation of the RII reflex in humans. *Pain*. 112:353-360, 2004
65. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. *Sleep*. 30:494-505, 2007
66. Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. *Expert review of neurotherapeutics*. 12:577-585, 2012
67. Staud R, Robinson ME, Vierck CJ, Jr., Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. *Pain*. 101:167-174, 2003
68. Sullivan M, Bishop S, Pivik J. The Pain Catastrophizing Scale: Development and Validation. *Psychological assessment*. 7:524-532, 1995
69. Sullivan MJ, Stanish WD. Psychologically based occupational rehabilitation: the Pain-Disability Prevention Program. *The Clinical journal of pain*. 19:97-104, 2003

70. Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC. Theoretical perspectives on the relation between catastrophizing and pain. *The Clinical journal of pain*. 17:52-64, 2001
71. Suokas AK, Walsh DA, McWilliams DF, Condon L, Moreton B, Wylde V, Arendt-Nielsen L, Zhang W. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis. Cartilage*. 20:1075-1085, 2012
72. Suzan E, Eisenberg E, Treister R, Haddad M, Pud D. A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: is hydromorphone therapy a double-edged sword? *Pain physician*. 16:65-76, 2013
73. Suzan E, Midbari A, Treister R, Haddad M, Pud D, Eisenberg E. Oxycodone alters temporal summation but not conditioned pain modulation: preclinical findings and possible relations to mechanisms of opioid analgesia. *Pain*. 154:1413-1418, 2013
74. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. *The journal of pain : official journal of the American Pain Society*. 5:133-137, 2004
75. Vaegter HB, Graven-Nielsen T. Pain modulatory phenotypes differentiate subgroups with different clinical and experimental pain sensitivity. *Pain*. 157:1480-1488, 2016
76. van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a model of endogenous pain modulation in clinical pain syndromes. *The journal of pain : official journal of the American Pain Society*. 11:408-419, 2010
77. Volkow ND, Baler RD. Addiction science: Uncovering neurobiological complexity. *Neuropharmacology*. 2013
78. Vowles KE, Gross RT, Sorrell JT. Predicting work status following interdisciplinary treatment for chronic pain. *European journal of pain (London, England)*. 8:351-358, 2004
79. Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study. *PloS one*. 8:e43896, 2013
80. Weissman-Fogel I, Sprecher E, Pud D. Effects of catastrophizing on pain perception and pain modulation. *Experimental brain research*. 186:79-85, 2008
81. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. *Anesthesiology*. 106:864-867, 2007
82. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*. 152:S2-15, 2011
83. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. *Current opinion in anaesthesiology*. 23:611-615, 2010
84. Yarnitsky D. Role of endogenous pain modulation in chronic pain mechanisms and treatment. *Pain*. 156 Suppl 1:S24-31, 2015
85. Yarnitsky D, Bouhassira D, Drewes AM, Fillingim RB, Granot M, Hansson P, Landau R, Marchand S, Matre D, Nilsen KB, Stubhaug A, Treede RD, Wilder-

- Smith OH. Recommendations on practice of conditioned pain modulation (CPM) testing. *European journal of pain (London, England)*. 2014
86. Yarnitsky D, Granot M, Granovsky Y. Pain modulation profile and pain therapy: between pro- and antinociception. *Pain*. 155:663-665, 2014
87. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. *Pain*. 153:1193-1198, 2012
88. Younger JW, Chu LF, D'Arcy NT, Trott KE, Jastrzab LE, Mackey SC. Prescription opioid analgesics rapidly change the human brain. *Pain*. 152:1803-1810, 2011
89. Yucel A, Ozyalcin S, Koknel Talu G, Kiziltan E, Yucel B, Andersen OK, Arendt-Nielsen L, Disci R. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. *European journal of pain (London, England)*. 9:407-416, 2005
90. Zhang Y, Ahmed S, Vo T, St Hilaire K, Houghton M, Cohen AS, Mao J, Chen L. Increased pain sensitivity in chronic pain subjects on opioid therapy: a cross-sectional study using quantitative sensory testing. *Pain medicine (Malden, Mass.)*. 16:911-922, 2015

Figure Legends

Table 1

Sample characteristics and descriptive data for main study variables

Table 2

Correlations among study measures

Table 3

Pressure pain thresholds and cold water pain during the conditioned pain modulation test

Table 4

Pinprick pain ratings during the temporal summation of pain test

Figure 1

Conditioned pain modulation scores for opioid users and non-users

Figure 2

Temporal summation of pain scores for opioid users and non-users

Figure 3

Association between conditioned pain modulation and temporal summation as a function of **individuals'** opioid status




Fig. 1. Conditioned pain modulation (CPM) scores for opioid users and non-users (mean \pm SEM). The CPM index represents the average of CPM trials; * $p < .05$

Temporal summation of pain index as a function of opioid use




Fig. 2. Temporal summation of pain (TSP) scores for opioid users and non-users (mean \pm SEM).

Figure 3
[Click here to download high resolution image](#)




Fig. 3. Association between conditioned pain modulation (CPM) and temporal summation (TSP) as a function of patient opioid status. $^{**} p < .01$

Table 1

Table 1
Sample characteristics and descriptive data for main study variables

| Variables | |
|---------------------------|-------------|
| Age | 49.5 ± 10.9 |
| Sex (% women) | 43 % |
| Ethnicity (% white) | 65 % |
| Pain duration (years) | 10.8 ± 8.6 |
| Pain location | |
| Back or neck pain | 100 % |
| Radiating pain; lower | 32 % |
| Radiating pain; upper | 47 % |
| Pain intensity (BPI) | 5.0 ± 2.4 |
| Pain interference (BPI) | 4.3 ± 2.9 |
| Catastrophizing (PCS) | 20.0 ± 12.1 |
| Depressive symptoms (BDI) | 11.6 ± 8.3 |

Note. ± represents standard deviations; BPI: Brief Pain Inventory; PCS: Pain Catastrophizing Scale; BDI: Beck Depression Inventory; Lower refers to legs and feet. Upper refers to shoulders and arms

Table 2

Table 2
Correlations among study measures

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|--------------------------------|---|------|------|--------|--------|--------|--------|------|--------|
| 1. Age | - | -.06 | .11 | -.37** | -.27** | -.31** | -.18** | .13 | .02 |
| 2. Opioid dose† | | - | -.12 | .08 | -.05 | -.10 | -.24 | .03 | -.13 |
| 3. Pain duration | | | - | .29* | .19 | .18 | .13 | -.24 | .18 |
| 4. Pain intensity (BPI) | | | | - | .71** | .51** | .32** | -.10 | .07 |
| 5. Pain interference (BPI) | | | | | - | .46** | .39** | -.04 | .00 |
| 6. Catastrophizing (PCS) | | | | | | - | .41** | -.14 | .15* |
| 7. Depressive symptoms (BDI) | | | | | | | - | .01 | .00 |
| 8. Conditioned pain modulation | | | | | | | | - | -.20** |
| 9. Temporal summation | | | | | | | | | - |

** Correlation is significant at the .01 level. * Correlation is significant at the .05 level. † Only among opioid users; BPI: Brief Pain Inventory; PCS: Pain Catastrophizing Scale; BDI: Beck Depression Inventory

Table 3

Pressure pain thresholds and cold water pain during the conditioned pain modulation (CPM) test

| | Opioid users | Non-users | <i>p</i> |
|-----------------|---------------|---------------|----------|
| CPM: Trial 1 | | | |
| PPTH-Pre | 373.5 (195.9) | 326.1 (120.2) | < .05 |
| Cold water pain | 52.2 (24.9) | 64.35 (26.5) | ns |
| PPTH-Post | 448.3 (234.9) | 422.8 (160.5) | ns |
| CPM: Trial 2 | | | |
| PPTH-Pre | 449.7 (223.1) | 331.9 (120.9) | < .05 |
| Cold water pain | 58.2 (26.3) | 68.7 (25.1) | ns |
| PPTH-Post | 517.3 (260.7) | 388.1 (137.9) | < .05 |

Note: PPTH-Pre: pressure pain thresholds before the water bath; Cold water pain: pain ratings during the water bath; PPTH-Post: Pressure pain thresholds 20 seconds after cold pain (i.e., water bath) onset; Numbers in parentheses are standard deviations.

Table 4
Pinprick pain ratings during the temporal summation of pain (TSP) test

| | Opioid users | Non-users | <i>p</i> |
|---------------------------|--------------|-------------|----------|
| TSP | | | |
| 1 st stimulus | 13.3 (14.3) | 16.3 (16.8) | ns |
| 10 th stimulus | 27.2 (23.9) | 29.8 (29.4) | ns |

Note: 1st stimulus refers to the pain rating (0-100) provided immediately after the first stimulus;
10th stimulus: Refers to the pain rating (0-100) provided immediately after the tenth stimulus.

**Endogenous pain modulation profiles among individuals with chronic pain:
Relation to opioid use**

Marc O. Martel, PhD^{1,2}, Kristian Petersen, PhD⁴, Marise Cornelius, BSc³,
Lars Arendt-Nielsen, PhD⁴, Robert Edwards, PhD³

¹ Faculty of Dentistry, McGill University, Montreal, Canada

² Department of Anesthesia, McGill University, Montreal, Canada

³ Department of Anesthesiology and Pain Medicine, Harvard Medical School, Brigham &
Women's Hospital, Boston, Massachusetts

⁴ SMI®, Department of Health Sciences and Technology, School of Medicine, Aalborg
University, Aalborg, Denmark

Address correspondence to:

Marc O. Martel, PhD. Strathcona Anatomy & Dentistry building, Rm M/71, 3640
University street, Montreal, Qc, Canada, H3A 2B2

Email: marc.o.martel@mcgill.ca

Disclosures

None of the authors have conflicts of interest to declare in relation to the submitted work. *Funding:* This work was supported by grants R21DA041020, and R01AG034982 (RRE, PI) from the National Institutes of Health grants and by a research collaborative grant from the International Association for the Study of Pain (IASP). None of the funding sources were involved in the collection, analysis, or interpretation of data. Funding sources were also not involved in manuscript preparation or in the decision to submit the article for publication.

Abstract

It is generally assumed that individuals exhibiting high pain inhibition also tend to exhibit low pain facilitation, but little research has examined this association in individuals with pain. The aims of this cross-sectional study were 1) to examine the association between measures of conditioned pain modulation (CPM) and temporal summation (TS) in individuals with chronic pain and 2) to examine whether this association was moderated by demographic (age, sex), psychological (depression, catastrophizing), or medication-related (opioid use) variables. individuals ($n = 190$) with back or neck pain completed questionnaires and underwent a series of quantitative sensory testing (QST) procedures assessing CPM and TS. Results indicated that individuals with higher levels of CPM showed lower levels of TS, $r = -.20$, $p < .01$. Analyses, however, revealed that the magnitude of this association was substantially weaker among opioid users ($r = -.08$, ns) than non-users ($r = -.34$, $p < .01$). None of the demographic or psychological variables included in our study influenced the association between CPM and TS. The magnitude of CPM was lower for opioid users than non-users, suggesting that opioid use might dampen the functioning of endogenous pain-inhibitory systems, and might contribute to a discordance between measures of pain inhibition and pain facilitation.

Perspective

Results of the present study indicated that greater endogenous pain-inhibitory capacity is associated with lower levels of pain facilitation. This association, however, was not significant among opioid users, suggesting that opioids might compromise the functioning and interrelationship between endogenous pain modulatory systems.

Keywords

Endogenous pain inhibition; pain facilitation; opioids; chronic pain

1.0. Introduction

It is well known that nociceptive signals can be modulated by central pain inhibitory and facilitatory processes^{1, 8, 82}. These pain-modulatory processes operate at various levels of the central nervous system and are assumed to play a determining role in the manifestations of chronic pain and in shaping inter-individual variability in the trajectory of many persistent pain conditions^{6, 25, 51, 83}. Considerable studies have been conducted using quantitative sensory testing (QST) to assess pain inhibition and pain facilitation^{9, 19, 71}. For instance, conditioned pain modulation (CPM) and temporal summation (TS) paradigms have been used as indices of pain-inhibitory and pain-summation processes^{1, 4, 8}. Evidence of impaired CPM and/or facilitated TS has been observed among individuals with a variety of chronic musculoskeletal, visceral, and neuropathic pain conditions (for reviews, see^{6, 48, 71, 76}).

There has been growing interest in characterizing individuals with chronic pain based on their pain modulation profiles (PMPs)^{4, 8, 56, 84, 86}, as inter-individual variability in pain modulation has been shown to predict clinical outcomes such as development or worsening of pain after surgery^{45, 55, 56}. Studies also found that TS is a predictor of responses to cyclooxygenase-2 (COX-2) inhibitors³ and that CPM is a predictor of responses to topical nonsteroidal anti-inflammatory drugs (NSAID)²⁷ as well as pregabalin treatment^{13, 87}. It has been argued that characterizing individuals with chronic pain based on their pain modulation profiles might provide valuable “mechanistic” information to clinicians in the context of pain assessment and individualized treatment selection^{25, 56, 75, 84, 86}.

One outstanding question in the literature on endogenous pain modulation is the manner in which pain-inhibitory processes (e.g., CPM) and pain-facilitatory processes (e.g., TS) inter-relate. For instance, some have hypothesized a concordance between these measures^{84, 86}, as individuals with low CPM would be expected to exhibit high TS, and vice versa. Psychophysical studies suggest that descending pain-inhibitory systems can modulate pain-facilitatory processes such as temporal summation^{33, 64, 67}. To date, however, it remains unclear whether individual differences in CPM and TS are associated, and very little research has been conducted on the nature of the association between these measures of pain modulation among individuals with chronic pain.

One of the few studies that has grouped together clusters of individuals with pain on the basis of both pain inhibition and pain facilitation reported an interactive effect of these measures, with those who had a combination of poor CPM and elevated TS showing the worst pain after joint replacement surgery⁵⁶. However, that study was not designed to evaluate the basal inter-correlation between CPM and TS, and it is unknown to what extent these factors tend to cluster within individual patients. Moreover, previous studies have shown that endogenous pain inhibition and pain summation may be influenced by a number of demographic variables, such as age and sex^{37, 48, 76}, and by psychological variables such as catastrophizing^{34, 38, 57, 80} and negative affect^{21, 39, 61}, which suggests that any CPM-TS relationships could be influenced by such variables. Furthermore, a number of studies have also shown that medications, such as opioids, may also affect endogenous pain-modulatory processes^{2, 60, 73}. Thus, there is reason to believe that some of these factors could contribute to

enhancing or decreasing the strength of the association between measures of pain inhibition and pain summation among individuals with pain.

The aims of this study were 1) to examine the association between measures of CPM and TS in a large cohort of individuals with chronic pain, 2) to examine the potential moderating role of demographic and psychological factors in the association between CPM and TS, and 3) to investigate the role of opioid use in the association between CPM and TS.

2.0. Methods

2.1. Participants

A sample of 190 individuals with chronic back or neck pain was included in this cross-sectional study. Participants were part of broader study project examining the psychophysical correlates of long-term opioid use. Although some data from the broader parent study were previously published ³⁵, this is our first report specifically examining the association between measures of CPM and TS. Participants in the parent study were recruited via treating physicians at Brigham and Women's Hospital (BWH) and local posting of print advertisements around the BWH Pain Management Center. Participants met the following inclusion criteria: (1) chronic back or neck pain, (2) had been experiencing pain for at least 6 months (3) able to speak, read, and write in English. They were excluded if (4) they had cancer, bone disease, heart disease, or a neurological disease, or (5) cognitive limitations that precluded providing self-report data. Individuals with (6) any active addiction problem (i.e., substance use disorder) were not included in the present study given the current clinical practice guidelines and principles at the BWH Pain Center regarding the management of patients with

substance use disorder (SUD). Patients with active SUD are generally referred to a local addiction treatment facility before undergoing pain treatment at the Pain Center and before being eligible for study participation. For the purposes of the present report, (7) individuals taking non-opioid adjuvant medications in addition to prescription opioids, such as antidepressants, anticonvulsants or sedatives were excluded from the study sample given the potential influence of these medications on endogenous pain modulatory systems ^{5, 7, 36, 79, 89}.

2.2. Procedure & measures

The Human Subjects Committee of BWH approved all study procedures. Interested participants underwent a telephone-based screening before coming in for the study visit. Upon arrival at the laboratory, participants underwent the process of providing informed consent, signed a consent form, and were asked to complete a demographic questionnaire, which included information about age, gender, and ethnicity. Participants also provided information on pain diagnosis and pain duration. They were then asked to report all the medications they were currently taking. Reports of medication were verified by a research assistant after the study session using the electronic medical record system, and published tables ²⁴ were used to convert opioid doses into morphine equivalent daily doses (MEDD). In addition to providing this information, participants were asked to complete self-report questionnaires assessing pain and psychological variables, and then underwent a series of standardized quantitative sensory testing procedures (see below).

2.2.1. Clinical pain severity

The Brief Pain Inventory (BPI ⁷⁴) was used as a measure of chronic pain severity. On the BPI, participants were asked to rate their average level of pain intensity (i.e., over the past 24 hours) on a numeric rating scale (NRS) that ranged from 0 (no pain) to 10 (extreme pain). Participants were also asked to rate the degree to which pain interferes with various domains of functioning on a NRS that ranged from 0 (does not interfere) to 10 (completely interferes). The BPI has been shown to be a reliable and valid measure of pain severity and pain interference among individuals with chronic pain ^{46, 47, 74}.

2.2.2. Pain catastrophizing

The Pain Catastrophizing Scale (PCS ⁶⁸) was used as a measure of catastrophic thinking about pain. The PCS contains 13 items describing different thoughts and feelings that individuals may experience when they are in pain. Participants were asked to reflect on past painful experiences and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on a 5-point scale ranging from 0 (not at all) to 4 (all the time). Numerous studies have supported the reliability and the validity of the PCS as a measure of pain-related catastrophic thinking among individuals with chronic pain ^{26, 54, 70}.

2.2.3. Depressive symptoms

The Beck Depression Inventory (BDI-II ¹⁰) was used as a measure of depressive symptomatology. The BDI-II consists of 21 items describing various symptoms of depression, and participants choose statements that describe how they have been feeling over the past two weeks. Responses are summed to yield an overall index of

depressive symptoms. The BDI has been shown to be a reliable and valid index of depressive symptoms among individuals with chronic pain ^{58, 69, 78}.

2.2.4. Quantitative sensory testing (QST)

During the QST session, participants were seated comfortably in a reclining chair while they underwent a standardized battery of psychophysical pain testing procedures. A trained research assistant sat with participants throughout the QST session. The QST session involved assessment of warmth and cool thresholds, heat pain thresholds (HPTh), cold pain thresholds (CPTh), and heat pain tolerance (HPTo), all tested on the ventral forearm. Pressure pain thresholds (PPT) at the joint of the thumb were also assessed. For purposes of the present study, only the mechanical temporal summation of pain (TS) and conditioned pain modulation (CPM) procedures are described below.

2.2.4.1. Temporal summation

Participants underwent an assessment of mechanical temporal summation using a set of 7 custom-made weighted pinprick stimulators developed by the German research Network on Neuropathic Pain ^{62, 63}. These punctuate mechanical probes have a flat contact area of .2 mm in diameter, and exert forces between 8 and 512 mN. Punctate stimuli were delivered to the skin on the dorsum of the middle finger of the right hand. Participants were first familiarized with the procedure by undergoing a practice trial (on the palm of their hand) during which we determined the lowest force stimulator that produced a painful sensation (128 or 256 mN for most participants). This force was then used to apply a train of 10 stimuli at the rate of 1 per second for the assessment of temporal summation. Participants rated the painfulness of the first, fifth, and tenth stimulus on a 0 to 100 verbal pain intensity scale. An index of temporal

summation was derived by subtracting participants' 1st pinprick pain rating from the last (10th) pinprick pain rating. Higher (positive) scores represented higher levels of temporal summation (i.e., pain facilitation) ^{32, 35}.

2.2.4.2. Conditioned pain modulation

In order to assess CPM, baseline pressure pain thresholds (PPTs) were first assessed using a handheld digital pressure algometer (Somedic, Hörby, Sweden) on the right upper trapezius, approximately 2 cm from the acromioclavicular joint. Given that participants had previously been familiarized with pressure pain threshold (PPT) assessment (assessed at the thumb) earlier during the QST session, CPM testing did not involve any practice trial. During baseline assessment of PPT at the trapezius, mechanical force was applied using a 0.5-cm² probe covered with polypropylene pressure-transducing material. Pressure was increased at a steady rate of 30 kPa/s until the subject indicated that the pressure was “first perceived as painful.” Immediately following the assessment of PPT, participants underwent a cold pressor test (CPT). During the CPT, participants immersed their contralateral (left) hand up to the wrist in a circulating cold water bath maintained at 4°C, a water temperature used as conditioning stimulus in many previous CPM studies ^{12, 38, 64}. Twenty seconds following hand immersion, PPT was reassessed on the right trapezius (i.e., the same site as baseline assessment). Participants were asked to remove their arm from the water 30 seconds after arm immersion. A second CPM trial was conducted two minutes after the end of the first CPM trial. The use of a 2-minute rest period between CPM trials is consistent with procedures that have been used in several previous CPM studies using the cold pressor test as the conditioning stimulus ^{30, 33, 38}. Assessing CPM twice is also

consistent with recommendations on CPM testing.⁸⁵ For each of the CPM trials, a CPM index was derived by calculating the percent ratio of PPT during CPT to PPT prior to CPT. Scores from these two CPM trials were averaged, and higher CPM scores represented greater pain-inhibitory capacity.^{28, 31, 65, 85}

3.0. Data Reduction and Analysis

All data were analyzed using IBM-SPSS v.21 (Chicago, IL, USA). The alpha level for significance was set to $p < .05$ for all analyses, and p-values above .05 are labeled in the Results section as NS (non-significant). Descriptive data for continuous variables were presented as means and standard deviations, and data for categorical variables were presented as percentages. Data for one of the CPM trials were missing for 7% of participants (i.e., 13/190). For these participants, data from the first CPM trial were used for the computation of the final CPM index.

Prior to conducting the primary study analyses, the potential confounding influence of ethnicity, clinical pain intensity, pain interference, and pain duration on CPM and TS was examined. Variables associated either with CPM or TS were retained as covariates in subsequent analyses.

A Pearson correlation was first computed to examine the association between CPM and TS. Pearson correlations were then computed to examine the association between psychological factors (i.e., catastrophizing, depressive symptoms) and endogenous pain modulation measures (i.e., CPM, TS), and independent samples t-tests were used to examine whether CPM and TS scores varied as a function of participant sex (i.e., men/women) and opioid status (i.e., opioid users/non-users).

In order to examine the potential moderating role of age, sex, opioid status, and psychological factors in the association between CPM and TS, five distinct moderation analyses were conducted using the PROCESS macro developed by Hayes et al.⁴³ For each of these moderation analyses, the TS index was used as the dependent variable, and two-way interaction terms between the CPM index and potential moderators (i.e., age, sex, opioid status, catastrophizing, depressive symptoms) were specified after inclusion of appropriate main effects. Any significant two-way interaction effect would suggest that the association between CPM and TS is moderated by participant age, sex, opioid status, catastrophizing, or depressive symptoms. Bias-corrected 95% confidence intervals (CI) were generated based on 5,000 bootstrap resamples, and CIs were presented along with p-values to interpret the significance of interaction/moderation effects. As recommended, moderation effects were considered significant in the case zero was not included within the CIs. Bootstrapping has been widely recommended because it improves power, but it was estimated that our sample size would be sufficient in order to detect medium-to-large effects using bootstrapping with two independent variables (IVs), an alpha set to .05, and a power of .80.⁴³

4.0. Results

4.1. Descriptive statistics

Descriptive statistics are presented in Table 1. In the present sample, 64 % (n = 122) of participants were taking opioids (average daily opioid dose = 101.0 morphine equivalents; SD = 114.8).

Prior to conducting primary analyses, the potential confounding influence of ethnicity, clinical pain intensity, pain interference, and pain duration on primary study

variables (i.e., CPM, TS) was examined. For opioid users, the influence of daily opioid dose on CPM and TS was also examined. None of these variables were significantly associated with either CPM or TS (see Table 2). Opioid users and non-users differed significantly on measures of clinical pain intensity ($t(176) = -7.3, p < .01$) and pain interference ($t(154) = -8.4, p < .01$), but not in pain duration.

4.2. Association between psychological factors and endogenous pain modulation

Table 2 also shows the correlations between psychological factors and endogenous pain modulation measures. Correlational analyses revealed a marginally significant negative association between catastrophizing and CPM ($r = -.14, p = .05$), indicating that higher levels of catastrophizing were associated with lower CPM. A significant positive correlation was found between catastrophizing and TS ($r = .15, p < .05$). Depressive symptoms were not significantly associated with either CPM or TS.

Independent samples t-tests were used to examine whether CPM and TS scores varied as a function of participant sex (i.e., men/women) and opioid status (i.e., opioid users/non-users). Results indicated that there were no significant sex differences either in CPM ($t(188) = 1.8, NS$) or TS ($t(188) = -.62, NS$). Results of t-tests, however, indicated a marginally significant difference in CPM as a function of opioid status, with lower CPM scores for opioid users than non-users, $t(188) = 2.1, p < .05$. Opioid users and non-users did not differ significantly on the TS index, $t(188) = -0.10, NS$ (see Figures 1 and 2).

4.3. Association between CPM and TS

A Pearson correlation was computed to examine the association between CPM and TS. Results revealed a significant negative correlation between CPM and TS

scores ($r = -.20$, $p < .01$), indicating that higher levels of CPM were associated with lower levels of temporal summation.

4.4. Moderators of the association between CPM and TS

As noted previously, five distinct bootstrapped moderation analyses were conducted to examine whether age, sex, opioid status, catastrophizing, or depressive symptoms moderated the association between CPM and TS. Results from these analyses indicated no significant 2-way interactions between CPM and participant age ($B = .001$, $SE = .004$, NS), sex ($B = .053$, $SE = .099$, NS), catastrophizing ($B = -.006$, $SE = .004$, NS), or depressive symptoms ($B = -.001$, $SE = .006$, NS). The two-way interaction effect between CPM and opioid status, however, was significant ($B = .194$, $SE = .091$, $p < .05$; LLCI = .014; ULCI = .375), indicating that the association between CPM and TS was moderated by participants' opioid status. Simple slope analyses were subsequently conducted in order to probe the interaction of CPM and opioid status on TS. As can be seen from Figure 3, the association between CPM and TS varied as a function of participants' opioid status (i.e., opioid users vs non-users). Results revealed a significant association between CPM and TS for non-users ($r = -.34$, $p < .01$), but not for opioid users ($r = -.08$, NS).

5.0. Discussion

Results of this study indicated that greater endogenous pain-inhibitory capacity is associated with lower levels of pain summation. Further, a moderation analysis revealed that the magnitude of this association differed significantly as a function of participants' opioid status, with opioid use appearing to reduce the magnitude of the inverse relationship between CPM and TS. None of the demographic or psychologic variables

included in the present study were found to moderate the association between CPM and TS.

The association that was found between CPM and TS is generally consistent with heuristic models of endogenous pain modulation that implicitly assume a certain degree of concordance between measures of pain inhibition and facilitation^{4, 20, 27, 66, 84, 86}. For instance, individuals exhibiting either high pain inhibition (high CPM), low pain summation (low TS), or both, have been collectively described as having an “antinociceptive” pain modulation phenotype, as opposed to a pro-nociceptive phenotype characterized by high TS and low CPM^{40, 86}. It is also noteworthy that individuals with chronic pain conditions characterized by “dysfunctional” pain modulation tend to show both decrements in CPM and elevations in TS relative to controls^{1, 8, 22, 23, 66}. On the basis of this model, one would expect an inverse association between indices of endogenous pain inhibition and endogenous pain facilitation, which is what we observed in the present study. In addition, two recent studies found that roughly 30 % of individuals with “normal” or “higher-than-average” CPM levels were characterized by low levels of TS^{56, 75}, which is also consistent with our results.

Interestingly, the present study found an association between measures of CPM and TS selectively among individuals who are not using opioids. While a number of factors might account for the altered association between CPM and TS among opioid users, our data suggest that this might be due at least in part to the potentially disruptive effects of exogenous opioids on individuals’ endogenous pain-inhibitory capacity. Consistent with previous work^{29, 59}, we found that the magnitude of CPM was lower for opioid users than non-users, suggesting that opioid use might dampen the functioning

of endogenous pain-inhibitory systems. Interestingly, several recent experimental studies have found that acute opioid administration may enhance endogenous pain inhibition ^{2, 53}, and other reports of short-term administration have suggested minimal effects ⁷³. Collectively, these findings may suggest that the impact of opioid use on indices of pain inhibition shows a biphasic time course, with acute potentiation of CPM followed by long-term decrements of CPM. There is now compelling evidence both from preclinical ^{15, 50} and clinical ^{77, 88} studies that opioid use, over time, may progressively lead to enduring neuroplastic changes at various levels of the central nervous system (CNS), including within neural pathways known to be involved in endogenous pain inhibition. To the extent that endogenous pain-inhibitory systems exert a modulatory influence upon pain summation ^{6, 25, 41, 81}, opioid-induced disruption of pain-inhibitory function might compromise the expected association between pain inhibition and pain facilitation, as observed among opioid users included in the present study. Although speculative, a disruption of pain-inhibitory function as a result of repeated opioid use might contribute to enhanced descending facilitatory activity and, in turn, to opioid-induced hyperalgesia (OIH), a phenomenon observed both experimentally and clinically ^{16, 17, 49, 72}. The observational nature of our study design prevents from concluding that opioid use caused hyperalgesic responses (i.e., opioid-induced hyperalgesia). However, the significantly lower pain-inhibitory (i.e., CPM) function and heightened clinical pain intensity levels observed among opioid users compared to non-users provide partial support for this notion. Previous studies among individuals with chronic pain have also observed disruptions in CPM ^{28, 60, 90} and heightened clinical pain intensity levels ^{17, 18} among long-term opioid users. However, given that these studies were also based on

observational study designs, research will be needed to determine whether a disruption of the association between pain-inhibitory and pain-facilitatory mechanisms may contribute to the development of opioid-induced hyperalgesia among individuals who initiate opioid therapy.

The findings of the present study have not only implications for conceptual models of endogenous pain modulation, but also for the assessment of pain-modulatory profiles in treatment settings. For instance, the modest overlap (i.e., concordance) between measures CPM and TS suggests considerable inter-individual heterogeneity within each of the pain modulation profiles. Consequently, in clinic settings, these two measures should not be used interchangeably to derive inferences about individuals' pain modulation. The predictive consideration of both CPM and TS paradigms is likely to yield a more reliable and comprehensive assessment of pain modulation profiles ⁵⁵. Our findings also suggest that a certain “discordance” between measures of endogenous pain inhibition (i.e., CPM) and pain facilitation (i.e., TS) might be more particularly pronounced among specific subgroups of individuals with chronic pain, such as those using opioid medication. Given that the coupling of high pain inhibition and low pain facilitation is viewed as an optimal pain modulation profile (i.e., an “antinociceptive” PMP) with the potential for buffering against negative pain-related outcomes ^{25, 84, 86}, the putative deleterious impact of opioids on individuals' pain modulation profiles should be considered over the course of treatment selection, either in the context of perioperative or chronic pain management. Future research should also examine whether the association between pain inhibition and pain facilitation is enhanced when individuals

are discontinuing or tapering off opioid medication, as well as the time course of these putative shifts in pain modulation produced by changes in opioid treatments.

A number of limitations must be considered when interpreting the present findings. First, this study report is based on a convenience sample, which limited our explanatory reach in accounting for some of the findings that were reported. Second, due to the cross-sectional nature of the study design, individuals' levels of CPM and TS were assessed only at a single point in time. While these two measures have been found to be relatively stable over time ^{11, 14, 42, 44, 52}, future studies involving repeated assessment of CPM and TS would allow one to derive more reliable inferences about the magnitude of the association between these two forms of endogenous pain modulation. Third, participants in the present study were taking relatively high doses of opioids considering recent changes in opioid prescribing guidelines ²⁴. Daily opioid doses were neither associated with CPM nor TS, but further studies will need to determine whether our findings can be generalized to patients taking lower opioid doses. It will also be important to further evaluate the influence of opioid dose and opioid use duration to the functioning of endogenous pain modulation systems. Fourth, individuals taking non-opioid analgesic medications were not included in the analyses. While this may be seen as a methodological strength, as it permitted us to rule out the influence of non-opioid medication on endogenous pain modulation, this places limits on the generalizability of our findings. Fifth, we did not measure potentially important variables, such as the duration of opioid therapy or the recency of opioid use in relation to QST. Future studies should control for inter-individual differences in these variables as they might influence measures of pain modulation. Finally, CPM was derived only on

the basis of the cold pressor test and pressure pain stimuli. Replication of our findings using other methods or CPM paradigms (i.e., using other conditioning and/or test stimuli) ⁴⁴ is warranted before drawing more firm conclusions regarding the association between CPM and TS.

Conclusion

Findings from the present study provide new insights into the association between endogenous pain-inhibitory and pain summation systems, showing an inverse relationship between CPM and TS among individuals with chronic pain. That is, those exhibiting higher levels of CPM showed lower levels of TS. While the coupling of high pain inhibition and low pain facilitation is viewed as an optimal endogenous pain modulation profile that may buffer against negative pain-related outcomes ^{25, 84}, the present findings suggest that opioid use might disrupt endogenous pain-inhibitory function and, in turn, the association between endogenous pain-inhibitory (i.e., CPM) and pain-facilitatory (TS) systems. Given that an impaired association between pain-inhibitory and pain-facilitatory systems is expected to increase individuals' vulnerability to poor pain-related outcomes ^{25, 56, 84}, further research will be needed to identify the factors that may impair the interrelationship between these endogenous pain modulatory systems. Research will also be needed to determine whether a disruption of the association between pain-inhibitory and pain-facilitatory mechanisms may contribute to long-term sensitization and hyperalgesic responses (i.e., opioid-induced hyperalgesia) among opioid users. Research in this area would provide additional insights into the potentially deleterious impact of opioids on endogenous pain

modulation systems, and would have implications for the management of individuals with pain conditions.

References

1. Arendt-Nielsen L. Central sensitization in humans: assessment and pharmacology. *Handb Exp Pharmacol*. 227:79-102, 2015
2. Arendt-Nielsen L, Andresen T, Malver LP, Oksche A, Mansikka H, Drewes AM. A double-blind, placebo-controlled study on the effect of buprenorphine and fentanyl on descending pain modulation: a human experimental study. *The Clinical journal of pain*. 28:623-627, 2012
3. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. *Pain*. 157:1634-1644, 2016
4. Arendt-Nielsen L, Egsgaard LL, Petersen KK, Eskehave TN, Graven-Nielsen T, Hoeck HC, Simonsen O. A mechanism-based pain sensitivity index to characterize knee osteoarthritis patients with different disease stages and pain levels. *Eur J Pain*. 19:1406-1417, 2015
5. Arendt-Nielsen L, Frokjaer JB, Staahl C, Graven-Nielsen T, Huggins JP, Smart TS, Drewes AM. Effects of gabapentin on experimental somatic pain and temporal summation. *Reg Anesth Pain Med*. 32:382-388, 2007
6. Arendt-Nielsen L, Graven-Nielsen T. Translational musculoskeletal pain research. *Best Pract Res Clin Rheumatol*. 25:209-226, 2011
7. Arendt-Nielsen L, Mansikka H, Staahl C, Rees H, Tan K, Smart TS, Monhemius R, Suzuki R, Drewes AM. A translational study of the effects of ketamine and pregabalin on temporal summation of experimental pain. *Reg Anesth Pain Med*. 36:585-591, 2011
8. Arendt-Nielsen L, Skou ST, Nielsen TA, Petersen KK. Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain. *Curr. Osteoporos. Rep*. 13:225-234, 2015
9. Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, Edwards RR, Freeman R, Gracely R, Haanpaa MH, Hansson P, Hatem SM, Krumova EK, Jensen TS, Maier C, Mick G, Rice AS, Rolke R, Treede RD, Serra J, Toelle T, Tugnoli V, Walk D, Walalce MS, Ware M, Yarnitsky D, Ziegler D. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. *Pain*. 154:1807-1819, 2013
10. Beck A, Steer R, Brown GK: *Manual for the Beck Depression Inventory-II.*, Psychological Corporation: San Antonio, TX, 1996.
11. Biurrun Manresa JA, Neziri AY, Curatolo M, Arendt-Nielsen L, Andersen OK. Test-retest reliability of the nociceptive withdrawal reflex and electrical pain thresholds after single and repeated stimulation in patients with chronic low back pain. *Eur J Appl Physiol*. 111:83-92, 2011
12. Bouhassira D, Moisset X, Jouet P, Duboc H, Coffin B, Sabate JM. Changes in the modulation of spinal pain processing are related to severity in irritable bowel

- syndrome. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*. 25:623-e468, 2013
13. Bouwense SA, Olesen SS, Drewes AM, van Goor H, Wilder-Smith OH. Pregabalin and placebo responders show different effects on central pain processing in chronic pancreatitis patients. *J Pain Res*. 8:375-386, 2015
14. Cathcart S, Winefield AH, Rolan P, Lushington K. Reliability of temporal summation and diffuse noxious inhibitory control. *Pain research & management*. 14:433-438, 2009
15. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. *British journal of pharmacology*. 154:384-396, 2008
16. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. *The Clinical journal of pain*. 24:479-496, 2008
17. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. *The journal of pain : official journal of the American Pain Society*. 7:43-48, 2006
18. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C, Mao J. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. *Reg Anesth Pain Med*. 33:199-206, 2008
19. Cruz-Almeida Y, Fillingim RB. Can quantitative sensory testing move us closer to mechanism-based pain management? *Pain Med*. 15:61-72, 2014
20. Cruz-Almeida Y, King CD, Goodin BR, Sibille KT, Glover TL, Riley JL, Sotolongo A, Herbert MS, Schmidt J, Fessler BJ, Redden DT, Staud R, Bradley LA, Fillingim RB. Psychological profiles and pain characteristics of older adults with knee osteoarthritis. *Arthritis Care Res (Hoboken)*. 65:1786-1794, 2013
21. de Souza JB, Potvin S, Goffaux P, Charest J, Marchand S. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. *The Clinical journal of pain*. 25:123-127, 2009
22. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. *Nat. Rev Rheumatol*. 9:340-350, 2013
23. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. Idiopathic pain disorders--pathways of vulnerability. *Pain*. 123:226-230, 2006
24. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *Jama*. 315:1624-1645, 2016
25. Edwards RR. Individual differences in endogenous pain modulation as a risk factor for chronic pain. *Neurology*. 65:437-443, 2005
26. Edwards RR, Bingham CO, 3rd, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. *Arthritis and rheumatism*. 55:325-332, 2006
27. Edwards RR, Dolman AJ, Martel MO, Finan PH, Lazaridou A, Cornelius M, Wasan AD. Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis. *BMC musculoskeletal disorders*. 17:284, 2016

28. Edwards RR, Dolman AJ, Michna E, Katz JN, Nedeljkovic SS, Janfaza D, Isaac Z, Martel MO, Jamison RN, Wasan AD. Changes in Pain Sensitivity and Pain Modulation During Oral Opioid Treatment: The Impact of Negative Affect. *Pain medicine (Malden, Mass.)*. 2016
29. Edwards RR, Dolman AJ, Michna E, Katz JN, Nedeljkovic SS, Janfaza D, Isaac Z, Martel MO, Jamison RN, Wasan AD. Changes in Pain Sensitivity and Pain Modulation During Oral Opioid Treatment: The Impact of Negative Affect. *Pain Med.* 17:1882-1891, 2016
30. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. *Pain.* 101:155-165, 2003
31. Edwards RR, Grace E, Peterson S, Klick B, Haythornthwaite JA, Smith MT. Sleep continuity and architecture: associations with pain-inhibitory processes in patients with temporomandibular joint disorder. *European journal of pain (London, England)*. 13:1043-1047, 2009
32. Edwards RR, Mensing G, Cahalan C, Greenbaum S, Narang S, Belfer I, Schreiber KL, Campbell C, Wasan AD, Jamison RN. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. *J. Pain Symptom. Manage.* 46:30-42, 2013
33. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in diffuse noxious inhibitory controls (DNIC): association with clinical variables. *Pain.* 106:427-437, 2003
34. Edwards RR, Smith MT, Stonerock G, Haythornthwaite JA. Pain-related catastrophizing in healthy women is associated with greater temporal summation of and reduced habituation to thermal pain. *The Clinical journal of pain.* 22:730-737, 2006
35. Edwards RR, Wasan AD, Michna E, Greenbaum S, Ross E, Jamison RN. Elevated pain sensitivity in chronic pain patients at risk for opioid misuse. *The journal of pain : official journal of the American Pain Society.* 12:953-963, 2011
36. Enggaard TP, Klitgaard NA, Gram LF, Arendt-Nielsen L, Sindrup SH. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. *Clinical pharmacology and therapeutics.* 69:245-251, 2001
37. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL, 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. *The journal of pain : official journal of the American Pain Society.* 10:447-485, 2009
38. Goodin BR, McGuire L, Allshouse M, Stapleton L, Haythornthwaite JA, Burns N, Mayes LA, Edwards RR. Associations between catastrophizing and endogenous pain-inhibitory processes: sex differences. *The journal of pain : official journal of the American Pain Society.* 10:180-190, 2009
39. Granot M, Weissman-Fogel I, Crispel Y, Pud D, Granovsky Y, Sprecher E, Yarnitsky D. Determinants of endogenous analgesia magnitude in a diffuse noxious inhibitory control (DNIC) paradigm: do conditioning stimulus painfulness, gender and personality variables matter? *Pain.* 136:142-149, 2008
40. Granovsky Y, Yarnitsky D. Personalized pain medicine: the clinical value of psychophysical assessment of pain modulation profile. *Rambam. Maimonides. Med. J.* 4:e0024, 2013

41. Graven-Nielsen T, Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. *Nature reviews. Rheumatology*. 6:599-606, 2010
42. Graven-Nielsen T, Vaegter HB, Finocchietti S, Handberg G, Arendt-Nielsen L. Assessment of musculoskeletal pain sensitivity and temporal summation by cuff pressure algometry: a reliability study. *Pain*. 156:2193-2202, 2015
43. Hayes AF: *Introduction to Mediation, Moderation, and Conditional Process Analysis, A Regression-Based Approach Methodology in the Social Sciences*. 2nd edition, Guilford Publications, 2017.
44. Imai Y, Petersen KK, Morch CD, Arendt Nielsen L. Comparing test-retest reliability and magnitude of conditioned pain modulation using different combinations of test and conditioning stimuli. *Somatosens Mot Res*. 33:169-177, 2016
45. Izumi M, Petersen KK, Laursen MB, Arendt-Nielsen L, Graven-Nielsen T. Facilitated temporal summation of pain correlates with clinical pain intensity after hip arthroplasty. *Pain*. 2016
46. Jamison RN, Link CL, Marceau LD. Do pain patients at high risk for substance misuse experience more pain? A longitudinal outcomes study. *Pain medicine (Malden, Mass.)*. 10:1084-1094, 2009
47. Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning? *The journal of pain : official journal of the American Pain Society*. 7:644-653, 2006
48. Lewis GN, Rice DA, McNair PJ. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. *The journal of pain : official journal of the American Pain Society*. 13:936-944, 2012
49. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. *Pain*. 100:213-217, 2002
50. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. *Annals of the New York Academy of Sciences*. 933:175-184, 2001
51. Marchand S. The physiology of pain mechanisms: from the periphery to the brain. *Rheum Dis Clin North Am*. 34:285-309, 2008
52. Martel MO, Wasan AD, Edwards RR. Sex differences in the stability of conditioned pain modulation (CPM) among patients with chronic pain. *Pain medicine (Malden, Mass.)*. 14:1757-1768, 2013
53. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. *Br. J. Anaesth*. 113:148-156, 2014
54. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. *J. Behav. Med*. 23:351-365, 2000
55. Petersen KK, Arendt-Nielsen L, Simonsen O, Wilder-Smith O, Laursen MB. Presurgical assessment of temporal summation of pain predicts the development of chronic postoperative pain 12 months after total knee replacement. *Pain*. 156:55-61, 2015

56. Petersen KK, Graven-Nielsen T, Simonsen O, Laursen MB, Arendt-Nielsen L. Preoperative pain mechanisms assessed by cuff algometry are associated with chronic postoperative pain relief after total knee replacement. *Pain*. 157:1400-1406, 2016
57. Piche M, Bouin M, Arsenault M, Poitras P, Rainville P. Decreased pain inhibition in irritable bowel syndrome depends on altered descending modulation and higher-order brain processes. *Neuroscience*. 195:166-175, 2011
58. Poole H, Bramwell R, Murphy P. Factor Structure of the Beck Depression Inventory-II in patients With chronic pain. *The Clinical journal of pain*. 22:790-798, 2006
59. Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain - new perspective of opioid-induced hyperalgesia. *Pain*. 139:431-438, 2008
60. Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain - new perspective of opioid-induced hyperalgesia. *Pain*. 139:431-438, 2008
61. Robinson ME, Wise EA, Gagnon C, Fillingim RB, Price DD. Influences of gender role and anxiety on sex differences in temporal summation of pain. *The journal of pain : official journal of the American Pain Society*. 5:77-82, 2004
62. Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Botefur IC, Braune S, Flor H, Hoge V, Klug R, Landwehrmeyer GB, Magerl W, Maihofner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. *Pain*. 123:231-243, 2006
63. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede RD. Quantitative sensory testing: a comprehensive protocol for clinical trials. *European journal of pain (London, England)*. 10:77-88, 2006
64. Serrao M, Rossi P, Sandrini G, Parisi L, Amabile GA, Nappi G, Pierelli F. Effects of diffuse noxious inhibitory controls on temporal summation of the RII reflex in humans. *Pain*. 112:353-360, 2004
65. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. *Sleep*. 30:494-505, 2007
66. Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. *Expert review of neurotherapeutics*. 12:577-585, 2012
67. Staud R, Robinson ME, Vierck CJ, Jr., Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. *Pain*. 101:167-174, 2003
68. Sullivan M, Bishop S, Pivik J. The Pain Catastrophizing Scale: Development and Validation. *Psychological assessment*. 7:524-532, 1995
69. Sullivan MJ, Stanish WD. Psychologically based occupational rehabilitation: the Pain-Disability Prevention Program. *The Clinical journal of pain*. 19:97-104, 2003

70. Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC. Theoretical perspectives on the relation between catastrophizing and pain. *The Clinical journal of pain*. 17:52-64, 2001
71. Suokas AK, Walsh DA, McWilliams DF, Condon L, Moreton B, Wylde V, Arendt-Nielsen L, Zhang W. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis. Cartilage*. 20:1075-1085, 2012
72. Suzan E, Eisenberg E, Treister R, Haddad M, Pud D. A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: is hydromorphone therapy a double-edged sword? *Pain physician*. 16:65-76, 2013
73. Suzan E, Midbari A, Treister R, Haddad M, Pud D, Eisenberg E. Oxycodone alters temporal summation but not conditioned pain modulation: preclinical findings and possible relations to mechanisms of opioid analgesia. *Pain*. 154:1413-1418, 2013
74. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. *The journal of pain : official journal of the American Pain Society*. 5:133-137, 2004
75. Vaegter HB, Graven-Nielsen T. Pain modulatory phenotypes differentiate subgroups with different clinical and experimental pain sensitivity. *Pain*. 157:1480-1488, 2016
76. van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a model of endogenous pain modulation in clinical pain syndromes. *The journal of pain : official journal of the American Pain Society*. 11:408-419, 2010
77. Volkow ND, Baler RD. Addiction science: Uncovering neurobiological complexity. *Neuropharmacology*. 2013
78. Vowles KE, Gross RT, Sorrell JT. Predicting work status following interdisciplinary treatment for chronic pain. *European journal of pain (London, England)*. 8:351-358, 2004
79. Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study. *PloS one*. 8:e43896, 2013
80. Weissman-Fogel I, Sprecher E, Pud D. Effects of catastrophizing on pain perception and pain modulation. *Experimental brain research*. 186:79-85, 2008
81. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. *Anesthesiology*. 106:864-867, 2007
82. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*. 152:S2-15, 2011
83. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. *Current opinion in anaesthesiology*. 23:611-615, 2010
84. Yarnitsky D. Role of endogenous pain modulation in chronic pain mechanisms and treatment. *Pain*. 156 Suppl 1:S24-31, 2015
85. Yarnitsky D, Bouhassira D, Drewes AM, Fillingim RB, Granot M, Hansson P, Landau R, Marchand S, Matre D, Nilsen KB, Stubhaug A, Treede RD, Wilder-

- Smith OH. Recommendations on practice of conditioned pain modulation (CPM) testing. *European journal of pain (London, England)*. 2014
86. Yarnitsky D, Granot M, Granovsky Y. Pain modulation profile and pain therapy: between pro- and antinociception. *Pain*. 155:663-665, 2014
87. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. *Pain*. 153:1193-1198, 2012
88. Younger JW, Chu LF, D'Arcy NT, Trott KE, Jastrzab LE, Mackey SC. Prescription opioid analgesics rapidly change the human brain. *Pain*. 152:1803-1810, 2011
89. Yucel A, Ozyalcin S, Koknel Talu G, Kiziltan E, Yucel B, Andersen OK, Arendt-Nielsen L, Disci R. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. *European journal of pain (London, England)*. 9:407-416, 2005
90. Zhang Y, Ahmed S, Vo T, St Hilaire K, Houghton M, Cohen AS, Mao J, Chen L. Increased pain sensitivity in chronic pain subjects on opioid therapy: a cross-sectional study using quantitative sensory testing. *Pain medicine (Malden, Mass.)*. 16:911-922, 2015

Figure Legends

Table 1

Sample characteristics and descriptive data for main study variables

Table 2

Correlations among study measures

Table 3

Pressure pain thresholds and cold water pain during the conditioned pain modulation test

Table 4

Pinprick pain ratings during the temporal summation of pain test

Figure 1

Conditioned pain modulation scores for opioid users and non-users

Figure 2

Temporal summation of pain scores for opioid users and non-users

Figure 3

Association between conditioned pain modulation and temporal summation as a function of individuals' opioid status

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No. | Recommendation | Page # where this item is located: |
|----------------------|----------|--|------------------------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 2 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3-4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5 |
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 5 |
| | | Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | |
| | | Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants | |
| | | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed | N/A |
| | | Case-control study—For matched studies, give matching criteria and the | |

| | | | |
|------------------------------|----|--|------|
| | | number of controls per case | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 6-9 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 6-8 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 9-10 |
| Study size | 10 | Explain how the study size was arrived at | 11 |
| Continued on next page | | | |

| | | | |
|------------------------|-----|---|------|
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 9-10 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 9-10 |
| | | (b) Describe any methods used to examine subgroups and interactions | 10 |
| | | (c) Explain how missing data were addressed | 9-10 |
| | | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy | N/A |
| | | (e) Describe any sensitivity analyses | N/A |
| | | Results | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 5 |
| | | (b) Give reasons for non-participation at each stage | N/A |
| | | (c) Consider use of a flow diagram | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 10 |
| | | (b) Indicate number of participants with missing data for each variable of interest | 9 |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | N/A |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | N/A |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | N/A |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | 9-10 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 9-13 |

| | | |
|--|--|-----|
| | (b) Report category boundaries when continuous variables were categorized | |
| | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |

Continued on next page

| | | | |
|--------------------------|----|--|-------|
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 12 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 13 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 16-17 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 13-16 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 17 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 1 |

THE JOURNAL OF PAIN
MANDATORY SUBMISSION FORM

SCAN SIGNED DOCUMENT AND UPLOAD WITH REVISION (or) EMAIL WITH NEW SUBMISSION TO JPAIN@JPAIN.US

ASSIGNED MANUSCRIPT NUMBER (if applicable):

A Signature Below Certifies Compliance With the Following Statements:

Copyright Transfer. In consideration of the acceptance of the above work for publication, I do hereby assign and transfer to The American Pain Society (APS) all rights, title, and interest in and to the copyright in the above titled work. This includes preliminary display/posting of the abstract of the accepted article in electronic form before publication. If any changes in authorship (order, deletions, or additions) occur after the manuscript is submitted, agreement by all authors for such changes must be on file with the APS. An author's name may only be removed at his/her own request. (Note: material prepared by employees of the US government in the course of official duties cannot be copyrighted.)

* For commercial companies, authorized agent signatures are allowed for copyright transfer but authors must sign for authorship responsibilities.

Authorship Responsibilities. I attest:

- 1) the manuscript is not currently under consideration elsewhere and the research reported will not be submitted for publication elsewhere until a final decision has been made as to its acceptability by the journal (**posting of submitted material on a web site is considered prior publication**);
- 2) the manuscript is truthful original work without fabrication, fraud, or plagiarism;
- 3) I have made an important scientific contribution to the study and am thoroughly familiar with the primary data; and
- 4) I have read the complete manuscript and take responsibility for the content and completeness of the manuscript and understand that if the paper, or part of the paper, is found to be faulty or fraudulent, I share responsibility.

Conflict of Interest Disclosure. All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged. Except as disclosed on a separate attachment, I certify that I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) that might pose a conflict of interest in connection with the submitted article (letter attached).

☐ Please check if this article was written as part of the official duties of an employee of the US Government.

Institutional Review Board/Animal Care Committee Approval. The undersigned author(s) certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and human principles of research.

Signature from EAC : s required (Email signed forms as attachments . May use multiple forms.)

| | | | |
|---------------|--------------|------------------------------------|----------------------|
| Signature (1) | <u>f!(μ:</u> | Print Name: <u>Mar.tse. Coww.o</u> | Date: <u>1/4g.ht</u> |
| Signature (2) | | Print Name: _____ | Date: _____ |
| Signature (3) | | Print Name: _____ | Date: _____ |
| Signature (4) | | Print Name: _____ | Date: _____ |
| Signature (5) | | Print Name: _____ | Date: _____ |
| Signature (6) | | Print Name: _____ | Date: _____ |

The Journal of Pain Editorial Office
JPAIN@JPAIN.US

(319) 430-4118

Submission link/ Guide for Authors: <http://ees.elsevier.com/jpain/>

<http://www.jpain.org>